Obatoclax and lapatinib interact to induce toxic autophagy through NOXA

Area of Science:

• Oncology
• Cell Biology
• Molecular Medicine

Background:

• Lapatinib, an ERBB1/2 inhibitor, faces resistance challenges in cancer therapy.
• Obatoclax, a B cell CLL/lymphoma-2 (BCL-2) family antagonist, has shown potential in overcoming drug resistance.
• Autophagy plays a complex role in cancer, acting as both a survival and cell death mechanism.

Purpose of the Study:

• To investigate the synergistic effects of combining lapatinib and obatoclax.
• To elucidate the underlying mechanisms of cell death induced by the drug combination, focusing on autophagy.
• To identify key molecular players involved in the drug-induced autophagic cell death.

Main Methods:

• Co-administration of lapatinib and obatoclax in cancer cells.
• Immunohistochemical analysis to detect protein localization (LC3, p62, LAMP2).
• Genetic manipulation (beclin 1 knockdown) and pharmacological inhibitors (3-methyladenine, chloroquine) to probe autophagic pathways.
• Western blotting to assess protein expression levels (MCL-1, BCL-2).

Main Results:

• The drug combination induced synergistic cell killing via autophagic cell death.
• Mitochondrial reactive oxygen species generation and increased p62 levels were upstream events.
• Activation of p38 MAPK and inactivation of mTOR were downstream events.
• Myeloid cell leukemia-1 (MCL-1) expression conferred protection against drug-induced lethality.
• Autophagy initiation was dependent on NOXA-mediated displacement of MCL-1 from beclin 1.
• Impaired autophagic degradation and disrupted autophagic flux led to toxic protein accumulation and mitochondrial dysfunction.

Conclusions:

• Lapatinib and obatoclax combination induces toxic autophagy through impaired autophagic degradation.
• The disruption of autophagic flux results in mitochondrial dysfunction and cell death.
• Targeting autophagic flux presents a potential therapeutic strategy to overcome resistance to ERBB1/2 inhibitors.